

3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

# **ProductInformation**

## **Oxypurinol**

Product Number **O 6881**Store at Room Temperature

## **Product Description**

Molecular Formula:  $C_5H_4N_4O_2$ Molecular Weight: 152.1 CAS Number: 2465-59-0  $\lambda_{max}$ : 251-253 nm (0.1 N HCI) Synonym: D-2-methylmalic acid

Oxypurinol is an allopurinol metabolite and an inhibitor of xanthine oxidase. Oxypurinol has shown preferential binding to the reduced form of xanthine oxidase. This leads to the diminished production of uric acid from hypoxanthine and xanthine in purine metabolism.

The role of oxypurinol in cyclosporin toxicity on cultured endothelial (EA) and epithelial cells has been investigated. Oxypurinol has been studied in hypercholesterolemic patients with regard to endothelial vasodilator function and xanthine oxidase inhibition.

### **Precautions and Disclaimer**

For Laboratory Use Only. Not for drug, household or other uses.

## **Preparation Instructions**

This product is soluble in 1 N NaOH (50 mg/ml), with heat as needed, to yield a clear to slightly hazy, light yellow solution.

#### References

- Elion, G. B., Enzymatic and Metabolic Studies with Allopurinol. Ann. Rheum. Dis., 25, 608-614 (1966).
- Spector, T., et al., Human and bovine xanthine oxidases. Inhibition studies with oxipurinol. Biochem. Pharmacol., 35(18), 3109-3114 (1986).
- Spector, T., Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem. Pharmacol., 37(2), 349-352 (1988).
- 4. Stryer, L., Biochemistry, 3rd ed., W.H. Freeman (New York, NY: 1988), pp. 619-621.
- Yang, J. J., and Finn, W. F., Effect of oxypurinol on cyclosporine toxicity in cultured EA, LLC-PK1 and MDCK cells. Ren. Fail., 20(1), 85-101 (1998).
- Cardillo, C., et al., Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension, 30(1 Pt 1), 57-63 (1997).

GCY/RXR 11/02